
1. vaccine. 2012 mar 30;30(16):2662-70. doi: 10.1016/j.vaccine.2012.02.010. epub
2012 feb 16.

assessing adequacy attenuation genetically modified malaria parasite
vaccine candidates.

annoura t(1), ploemen ih, van schaijk bc, sajid m, vos mw, van gemert gj,
chevalley-maurel s, franke-fayard bm, hermsen cc, gego a, franetich jf, mazier d,
hoffman sl, janse cj, sauerwein rw, khan sm.

author information: 
(1)leiden malaria research group, department parasitology, leiden university
medical center, 2333 za leiden, netherlands.

the critical first step clinical development malaria vaccine, based
on live-attenuated plasmodium falciparum sporozoites, guarantee of
complete arrest liver. report approach assessing adequacy 
attenuation genetically attenuated sporozoites vivo using plasmodium
berghei model malaria p. falciparum sporozoites cultured primary human 
hepatocytes. show two genetically attenuated sporozoite vaccine
candidates, δp52+p36 δfabb/f, adequately attenuated. sporozoites
infection mice p. berghei candidates result blood infections.
we also provide evidence p. falciparum sporozoites leading vaccine
candidate similarly attenuated deletion genes encoding
the proteins p52 p36, develop replicating liver stages. therefore,
we propose minimal set screening criteria assess adequacy sporozoite
attenuation necessary advancing clinical development and
studies humans.

copyright â© 2012 elsevier ltd. rights reserved.

doi: 10.1016/j.vaccine.2012.02.010 
pmid: 22342550  [indexed medline]

